Selected Recent Articles

• FDA Approved Changes to the Genvoya Label.  (September 2016, TheBodyPro)
• FDA Approved Changes to the Sustiva Label.  (September 2016, TheBodyPro)
• FDA Approves Once-Daily Hepatitis C Regimen Viekira XR.  (July 2016, Hepmag)
• FDA approves expanded Prezista label for pregnant women with HIV.  (July 2016, Healio)
• FDA Approves Epclusa Combo Pill for All Types of Hepatitis C.  (July 2016, Beta Blog); related coverage from NEJM Journal Watch
• FDA updates Prezista recommendations for pregnant women with HIV.  (June 2016, Healio)
• Descovy, New HIV Drug Containing Tenofovir Alafenamide, Approved by FDA.  (April 2016, TheBodyPRO); related coverage from Beta Blog, Healio, and Poz
• FDA to Place “Black Box” Warnings on All Prescription Opioids.  (March 2016, Hepmag)
• FDA updates Complera label for use in children aged older than 12 years.  (March, Healio)
• FDA OKs Gilead’s Genvoya, First HIV Combo Pill With New Tenofovir.  (November 5, 2015, Poz)
• FDA Warns of Serious Liver Injury Risk with Hepatitis C Treatments Viekira Pak and Technivie.  (October 2015, FDA and TheBodyPro)
• Cobicistat and elvitegravir approved in the U.S. as single pills.  (September/October 2014, HIV Treatment Bulletin)
• Single-pill dolutegravir/abacavir/3TC (Triumeq) approved in EU and US.  (September/October 2014, HIV Treatment Bulletin)
• New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless…  (September 2014, Journal Watch)
• HIV/AIDS Update – Approval of Vitekta.  (September 2014, U.S. Food and Drug Administration)
• HIV/AIDS Update: Approval of Tybost (cobicistat) 150 mg tablets.  (September 2014, U.S. Food and Drug Administration)
• Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved as Individual HIV Drugs.  (September 2014, TheBody)
• FDA Approves Gilead’s Vitekta (Elvitegravir) to Treat HIV.  (September 2014, Poz)
• FDA Approves HIV Treatment Boosting Agent Tybost (Cobicistat)  (September 2014, Poz)
• FDA Approves New Single-Tablet HIV Regimen, Triumeq.  (August 2014, Poz)
• FDA OKs Oral Isentress to Treat HIV in Children.  (January 2014, Poz)
• Government Shutdown May Slow FDA Drug Approvals.  (September 2013, Poz)
• FDA Approves HIV Drug Tivicay (Dolutegravir)  (August 2013, Poz)
• FDA OKs First Rapid Test That Can Detect Acute HIV.  (August 2013, Poz)
• FDA OKs Generic Truvada for Use Abroad.  (August 2013, Poz)
• FDA Approves Sustiva for Children 3 Months to 3 Years Old.  (May 2013, Poz)
• FDA Updates Atripla Label.  (April 2013, Poz)
• FDA Approves Changes to Reyataz Label.    (February 2013, Poz)
• FDA Releases Updated Drug Interaction Information for Kaletra.  (February 2013, Poz)